- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04418011
Neuromodulation of Social Cognitive Circuitry in People With Schizophrenia Spectrum Disorders (ModSoCCS)
Study Overview
Status
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Aristotle Voineskos, MD
- Phone Number: 34378 416-535-8501
- Email: aristotle.voineskos@camh.ca
Study Contact Backup
- Name: Dielle Miranda, MA
- Phone Number: 33120 416-535-8501
- Email: dielle.miranda@camh.ca
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada
- Centre for Addiction and Mental Health
-
-
-
-
Maryland
-
Catonsville, Maryland, United States, 21228
- Maryland Psychiatric Research Centre
-
-
New York
-
Manhasset, New York, United States, 11030
- The Feinstein Institute for Medical Research
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 18-55 years;
- Male or Female;
- DSM-5 diagnosis of schizophrenia, schizoaffective disorder, or schizophreniform disorder; other specified psychotic disorder (documented by SCID-5);
- Prescription of antipsychotic medication for at least 60 days and constant dose for 30 days prior to study entry (either first or second generation antipsychotics permitted);
- Able to participate in the informed consent process and provide voluntary informed consent.
Exclusion Criteria:
- DSM-5 substance use disorder (other than caffeine, mild cannabis use, or tobacco) within the past six months; or a positive baseline urine drug screen (except cannabis for mild use). Only participants meeting a moderate to severe cannabis use disorder will be excluded
- Type 1 diabetes mellitus (i.e., insulin-dependent diabetes mellitus with onset < 35 years of age and/or diabetes mellitus that has been complicated by a prior documented episode of ketoacidosis)
- Acute or unstable medical illness (e.g. delirium, cancer, uncontrolled diabetes, decompensated cardiac, hepatic, renal or pulmonary disease, stroke, or myocardial infarction), whose pathology or treatment could alter the presentation or treatment of schizophrenia or significantly increase the risk associated with the proposed treatment protocol
- Neurological disease associated with extrapyramidal signs and symptoms (e.g. Parkinson's disease); epilepsy (i.e. seizures not due to medication/drugs or due to fever) or physical signs of stroke; any diagnosis of a Central Nervous System (CNS) disorder
- Requires a benzodiazepine with a regular dose equivalent to lorazepam 2 mg/day or higher or any anticonvulsant due to the potential of these medications to limit the efficacy of rTMS
- Suspected DSM-5 intellectual disability based upon clinical interview and psychosocial history or estimated IQ of <71
- Prior Psychosurgery
- Presence of MRI contraindications (e.g. pacemakers)
- Pregnancy (self-report)
- rTMS treatment in the last 5 years
- Non-English speakers
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Active 10 Hz rTMS
Active treatment will be targeted to an intensity that is 120% of the resting motor threshold.
Stimulation will be delivered at 10 Hz according to conventional FDA-approved parameters (4 s on and 26 s off; 3000 pulses per session; total duration 37.5 mins) .
|
The present study aims to use both repetitive transcranial magnetic stimulation (rTMS) and intermittent theta burst stimulation (iTBS), safe and effective forms of neuromodulation, to target the neural circuitry of social cognitive (SCog) impairments in people with SSDs. Treatment sessions will be administered five days per week for two weeks. Other Name: MagPro X100 or R30 (Medtronic A/S. Copenhagen, Denmark) equipped with a Cool-B70 A/P coil and Qooler fluid-cooling device (MagVenture, Farum, Denmark), positioned under MRI guidance using the Brainsight neuronavigation system (Rogue Resolutions, Montreal, Canada) or Localite (Localite GmbH, Bonn, Germany) |
Active Comparator: Active iTBS
Active iTBS will be targeted to an intensity that is 120% of the resting motor threshold.
Stimulation will be delivered in triplet 50 Hz bursts, repeated at 5 Hz; 2 seconds on and 8 seconds off; 600 pulses per session; total duration of 3 min 9 seconds.
|
The present study aims to use both repetitive transcranial magnetic stimulation (rTMS) and intermittent theta burst stimulation (iTBS), safe and effective forms of neuromodulation, to target the neural circuitry of social cognitive (SCog) impairments in people with SSDs. Treatment sessions will be administered five days per week for two weeks. Other Name: MagPro X100 or R30 (Medtronic A/S. Copenhagen, Denmark) equipped with a Cool-B70 A/P coil and Qooler fluid-cooling device (MagVenture, Farum, Denmark), positioned under MRI guidance using the Brainsight neuronavigation system (Rogue Resolutions, Montreal, Canada) or Localite (Localite GmbH, Bonn, Germany) |
Sham Comparator: Sham rTMS
Sham stimulation will be delivered using the same stimulation parameters as either 10 Hz rTMS or iTBS. For both active and sham stimulation, TMS coil positioning for each individual will be optimized by combining participant fMRI data, meta-analytic functional analysis, electric field modelling, and real-time neuronavigation. |
Other Name: MagPro X100 or R30(Medtronic A/S.
Copenhagen, Denmark) equipped with a Cool-B70 A/P coil and Qooler fluid-cooling device (MagVenture, Farum, Denmark), positioned under MRI guidance using the Brainsight neuronavigation system (Rogue Resolutions, Montreal, Canada) or Localite (Localite GmbH, Bonn, Germany)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in mentalizing brain network functional connectivity
Time Frame: 2 weeks
|
Measured using the empathic accuracy fMRI task
|
2 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treatment Tolerability
Time Frame: 2 weeks
|
Measured using the Visual Analogue Scale for Pain (VAS)
|
2 weeks
|
Treatment Tolerability
Time Frame: 2 weeks
|
Measured using proportion of participants that report headache
|
2 weeks
|
Treatment Tolerability
Time Frame: 2 weeks
|
Measured using proportion of participants that report dizziness
|
2 weeks
|
Treatment Tolerability
Time Frame: 2 weeks
|
Measured using proportion of treatment related SAE's
|
2 weeks
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Anil Malhotra, MD, The Feinstein Institute for Medical Research, Zucker Hillside Hospital
- Principal Investigator: Robert Buchanan, MD, Maryland Psychiatric Research Centre, University of Maryland
- Principal Investigator: Aristotle Voineskos, MD, Centre for Addiction and Mental Health
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 133/2019
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Bradley LegaRecruiting
-
All India Institute of Medical Sciences, BhubaneswarRecruitingTreatment Resistant SchizophreniaIndia
-
King's College LondonSouth London and Maudsley NHS Foundation TrustRecruitingTreatment-resistant Schizophrenia | Healthy Controls | Treatment-responsive SchizophreniaUnited Kingdom
-
University of Sao PauloUnknownRefractory Schizophrenia | Super Refractory SchizophreniaBrazil
-
Peking UniversityNot yet recruitingTreatment-resistant Schizophrenia
-
Rakitzi, StavroulaActive, not recruiting
-
Ohio State UniversityRecruitingTreatment-resistant SchizophreniaUnited States
-
University Hospital, BrestRecruitingSchizophrenia | Schizophrenia Prodromal | Schizophrenia, ChildhoodFrance
Clinical Trials on Repetitive Transcranial Magnetic Stimulation
-
State University of New York - Upstate Medical...RecruitingHeadache | Brain Concussion | Mild Traumatic Brain Injury | Post-Concussion SymptomsUnited States
-
Xuzhou Central HospitalThe Affiliated Hospital of Xuzhou Medical UniversityNot yet recruitingFunctional Magnetic Resonance Imaging | Executive Function Disorder
-
Al-Azhar UniversityCompleted
-
Guangzhou Psychiatric HospitalCompletedCognitive Impairment | Bipolar Disorder | RelapseChina
-
Fatih Sultan Mehmet Training and Research HospitalCompletedFailed Back Surgery Syndrome
-
Veterans Medical Research FoundationUnited States Department of DefenseCompletedHeadache | Gulf War SyndromeUnited States
-
Yi YangRecruitingTranscranial Magnetic StimulationChina
-
Yi YangRecruitingTranscranial Magnetic StimulationChina
-
First Affiliated Hospital of Zhejiang UniversityCompletedBipolar DisorderChina
-
Izmir Katip Celebi UniversityCompletedPost-stroke Shoulder PainTurkey